Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17461845 | 0.91 | NPC1 (0.43) | NPC1CNR2ALDH1A1HPGDSTING1 | |
| SCHEMBL16093815 | 0.88 | NPC1 (0.54) | NPC1CNR2ALDH1A1HPGDTP53 | |
| SCHEMBL16120028 | 0.87 | CNR2 (0.43) | CNR2ALDH1A1HPGDTP53 | |
| SCHEMBL17461831 | 0.81 | MAP2K2 (0.37) | NPC1CNR2ALDH1A1CNR1 | |
| SCHEMBL16120106 | 0.81 | JAK2 (0.39) | NPC1CNR2 | |
| SCHEMBL16120022 | 0.80 | ALDH1A1 (0.65) | NPC1CNR2ALDH1A1HPGDCNR1 | |
| SCHEMBL17461821 | 0.80 | NPC1 (0.52) | NPC1CNR2ALDH1A1HPGDCNR1 | |
| SCHEMBL17461830 | 0.78 | CNR2 (0.41) | NPC1CNR2ALDH1A1HPGDCNR1 | |
| SCHEMBL16099272 | 0.78 | HPGD (0.60) | NPC1CNR2ALDH1A1HPGDTP53 | |
| SCHEMBL17461862 | 0.77 | CNR2 (0.45) | CNR2ALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | PANACELA LABS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | PANACELA LABS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014153055-A2 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153043-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | AR, KLK3, BRDT | NPC1 2157/4885CNR2 204/4885ALDH1A1 371/4885 |
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | KLK3, AR, BRDT | NPC1 3120/4885CNR2 682/4885ALDH1A1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.